Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial
ObjectiveVunakizumab, a novel IL-17A inhibitor, has demonstrated satisfactory efficacy and safety for the treatment of moderate-to-severe plaque psoriasis. This analysis aimed to assess the impact of treatment interruption on the efficacy and safety of vunakizumab in the treatment of this disease.Me...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Frontiers Media S.A.
2026-01-01
|
| Sraith: | Frontiers in Immunology |
| Ábhair: | |
| Rochtain ar líne: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1639049/full |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|